Gene therapy: primed for take-off.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Nonviral Gene Therapy for Cancer: A Review.Diseases (Basel, Switzerland) · 2018
   Review
2. Self-assembly of c-myc DNA promoted by a single enantiomer ruthenium complex as a potential nuclear targeting gene carrier.Scientific reports · 2016
   Article
3. Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene.International journal of nanomedicine · 2016
   Article
4. Hybrid biosynthetic gene therapy vector development and dual engineering capacity.Proceedings of the National Academy of Sciences of the United States of America · 2014
   Article
5. A Winning New Combination? Toward Clinical Application in Oncology.Cancer control : journal of the Moffitt Cancer Center
   Review

Corrections and comments

• Comment on
  Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.2013
• Comment on
  Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as